Egis Pharmaceuticals made a net profit of HUF 18,531 mil in 2012, up 36.4% compared to the previous year. Historically, between 2000 and 2012, the company's net profit reached a high of HUF 18,531 mil in 2012 and a low of HUF 5,540 mil in 2003.
The result implies a return on equity of 10.9% and a return on invested capital of 14.1% in 2012. That is compared to an average of 10.6% and 12.8% over the last five years.
The company has been operating with average EBITDA margin of 19.4% in the last 5 years and an average net margin of 12.3%.
Since 2007, the firm's net profit increased by 143% or an average of 19.4% a year.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter generated ROE of 9.76% and ROCE of 9.83% in 2012. Krka's profitability reached 13.4% and 11.1%, respectively. Sanofi-Aventis Czech Republic operated with 8.21% and 2.37% returns in 2012.
You can see all the company’s data at Egis Pharmaceuticals profile, or you can download a report on the company in the report section.
Helgi Library 
